(Press-News.org) SAN FRANCISCO (March 10, 2013) —High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. This group of patients is at high risk for kidney damage related to contrast agents used in imaging tests.
Previous studies have demonstrated the kidney-protective value of various statins administered before patients undergo angioplasty. Rosuvastatin was chosen for this phase IV study because inflammation is involved in development of both acute coronary syndrome and kidney injury, and the drug has anti-inflammatory properties and reported clinical benefits in preventing events that can harm the heart. U.S. and European guidelines recommend statins for all acute coronary syndrome patients, regardless of cholesterol levels, within one to four days after admission.
A total of 504 patients were randomly assigned to the statin or control group. None of the patients had taken statins before; all were slated for diagnostic angiographic imaging with intent to perform angioplasty, had iodixanol injected for imaging and had non-ST elevation acute coronary syndrome, which carries high risk for heart attack. The statin patients received one 40-mg dose of rosuvastatin as soon as they were admitted to the coronary care unit plus a single 20-mg dose daily until they were discharged, then continued with post-discharge rosuvastatin at 20 mg/day or 10 mg/day, depending on kidney function determined by creatinine clearance. The control group received atorvastatin at 40 mg/day after discharge and no statin before then.
On the primary endpoint—contrast-induced acute kidney injury, defined as a rise in creatinine of at least 0.5 mg/dl or at least 25 percent from baseline within 72 hours—the statin group had significantly better results (6.7 percent vs. 15.1 percent). Rosuvastatin showed comparable benefits with other definitions of kidney injury as well: creatinine increase of at least 0.3 mg/dl from baseline within 48 hours (3.6 vs. 8.7 percent) and within 72 hours (4.4 vs. 10.7 percent).
"The beneficial impact of statin pre-administration was consistent in all subgroups and in particular in patients with kidney dysfunction shown by creatinine clearance less than 60 ml/min, where kidney injury incidence was 8.6 percent compared with 20.9 percent in the control group," said Anna Toso, MD, clinical and interventional cardiologist with the Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy, and the study's principal investigator.
The number of ACS patients who undergo angiographic procedures is growing and includes a population that's getting more elderly and has more risk factors, she noted.
The statin group also demonstrated superior results for 30-day adverse clinical events of death, dialysis, heart attack, stroke and persistent kidney damage, with cumulative incidence of 3.9 percent compared with 7.9 percent for the control group.
"Our study shows that early administration of high-dose statin has a protective effect against kidney damage due to contrast medium in patients with ACS," Dr. Toso said. "The results help define better the timing of early administration of statins, which should be given as soon as possible after admission and always before the angiographic procedure, to reduce kidney complications and achieve clinical benefits, even before hospital discharge."
This research is part of the larger PRATO-ACS clinical project to explore rosuvastatin's pleiotropic effects—actions other than those for which the drug was developed (in this case, lowering cholesterol)—on a number of targets, including contrast-induced acute kidney injury.
"It would be interesting to compare the effects of lipophilic and hydrophilic statins," Dr. Toso said. "We are now planning the PRATO-ACS 2 project, a head-to-head comparison between high-dose rosuvastatin [hydrophilic] and high-dose atorvastatin [lipophilic] administered on admission to statin-naïve ACS patients scheduled for early invasive strategy."
Researchers say a multicenter study is needed. The PRATO-ACS study was supported by the nonprofit Centro Cardiopatici Toscani. Dr. Toso indicated no conflict of interest to disclose.
### The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.
The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.
Drug protects against kidney injury from imaging dye in ACS patients
2013-03-11
ELSE PRESS RELEASES FROM THIS DATE:
Encouraging early results for redesigned Sapien valve
2013-03-11
SAN FRANCISCO (March 10, 2013) — The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
PARTNER II is the first randomized clinical trial involving the Sapien XT valve and the only one that compares the new device to the original FDA-approved Sapien ...
New biolimus stent equal to everolimus stent at 1 year
2013-03-11
SAN FRANCISCO (March 10, 2013) — In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Drug-eluting stents are structures placed inside narrowed coronary arteries to restore proper blood flow. A polymer coating on these devices slowly releases a drug designed to prevent restenosis—another blockage at the same site—and prevent a second ...
Fewer adverse events with 'double kissing' crush stent than culotte
2013-03-11
SAN FRANCISCO (March 10, 2013) — Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session.
DKCRUSH-III is the first head-to-head comparison of double kissing (DK) crush and culotte stent techniques in coronary artery disease. The study focused on bifurcation lesions, which involve a main branch and a smaller side branch ...
Cangrelor superior to clopidogrel in CHAMPION PHOENIX trial
2013-03-11
SAN FRANCISCO (March 10, 2013) — The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Cangrelor and clopidogrel interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting. Currently approved drugs in this class are effective in cutting down ischemic events—blood-flow reductions ...
New anti-clotting drug more effective than current treatment
2013-03-11
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.
Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures. ...
Magnet ingestion by young children serious and growing problem
2013-03-11
Physicians and parents must be aware of the growing danger of magnet ingestion by children because magnets can adhere to each other and cause life-threatening problems such as bowel perforations, a new case study illustrates in CMAJ.
"Modern magnet technology has transformed what was once an esoteric subtype of foreign-body ingestion into a common and lethal threat," writes Dr. Daniel Rosenfield, Department of Paediatrics, The Hospital for Sick Children (SickKids), with coauthors.
In the past, magnet ingestion generally could be treated with a wait-and-see approach, ...
Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
2013-03-11
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells – without affecting surrounding, healthy cells.
The first study, published today in the journal Oncogene, worked with acute myeloid leukemia (AML), for which current chemotherapies offer a cure rate of only about 55 percent.
"In about 2/3 of all AML patients and about 90 percent of adult AML patients, we found that the Mer receptor was upregulated. Mer receptor protein ...
EARTH: Well-healed faults produce high-frequency earthquake waves
2013-03-11
Alexandria, VA – Much like our voices create sound waves with a variety of low and high pitches, or frequencies, earthquakes produce seismic waves over a broad spectrum. The seismic waves' frequencies determine, in part, how far they travel and how damaging they are to human-made structures. However, the inaccessibility of fault zones means that very little is known about why and how earthquakes produce different frequencies. With the help of a new tabletop model, scientists have now identified how a process known as fault healing can shape seismic waves and potentially ...
BGI Tech develops novel 'Ultra-Deep de novo' assembly solution for heterozygous genomes
2013-03-11
Shenzhen, China, March 11, 2013- BGI Tech Solutions Co., Ltd., also referred to as "BGI Tech", introduced today its novel assembly solution for facilitating heterozygous genomes research. This marks another technological breakthrough for BGI in heterozygous genome assembly after the completed genome sequencing of oyster, diamondback moth and pear.
The availability of a reference genome for a species is the cornerstone for the in-depth understanding of its biological secrets and commercial values. However, a major obstacle that prevents scientists to easily crack the genome ...
Gun retailers take a hard line on illegal firearm sales, UC Davis survey finds
2013-03-11
(SACRAMENTO, Calif.) —A scientific survey of more than 1,600 gun retailers in the U.S. has found that gun buyers frequently try to make illegal purchases and that gun retailers take a dim view of fellow sellers who engage in illegal activity — regardless of whether they are actively breaking the law or simply looking the other way.
The survey, conducted in 2011 by Garen Wintemute, professor of emergency medicine and director of the UC Davis Violence Prevention Research Program, is believed to be the first scientific study of a large group of gun retailers to determine ...